Should I buy or sell Travere Therapeutics stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TVTX shares. View TVTX analyst ratings or view top-rated stocks .

What is Travere Therapeutics' stock price target for 2024?

15 equities research analysts have issued twelve-month price targets for Travere Therapeutics' shares. Their TVTX share price targets range from $9.00 to $35.00. On average, they anticipate the company's share price to reach $17.85 in the next year. This suggests a possible upside of 215.3% from the stock's current price. View analysts price targets for TVTX or view top-rated stocks among Wall Street analysts .

How have TVTX shares performed in 2024?

Travere Therapeutics' stock was trading at $8.99 at the beginning of 2024. Since then, TVTX shares have decreased by 37.0% and is now trading at $5.66. View the best growth stocks for 2024 here .

When is Travere Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our TVTX earnings forecast .

How were Travere Therapeutics' earnings last quarter?

Travere Therapeutics, Inc. (NASDAQ:TVTX) announced its quarterly earnings data on Thursday, February, 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.11. The firm earned $45.06 million during the quarter, compared to analyst estimates of $41.25 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 177.97% and a negative net margin of 56.02%.

What ETF holds Travere Therapeutics' stock?

Virtus LifeSci Biotech Products ETF holds 44,150 shares of TVTX stock, representing 1.52% of its portfolio.

Who are Travere Therapeutics' major shareholders?

Travere Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.12%) and Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed , Eric M Dube , Jula Inrig, Laura Clague , Noah L Rosenberg , Peter Heerma , Sandra Calvin , Steve Aselage and William E Rote . View institutional ownership trends .

How do I buy shares of Travere Therapeutics?

Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TVTX

Travere Therapeutics (TVTX) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free TVTX Stock Alerts

$5.72

-0.08 (-1.38%)

(As of 05:21 PM ET)

Compare

Today's Range: $5.57
▼
$5.91
50-Day Range: $5.80
▼
$8.86
52-Week Range: $5.25
▼
$22.75

Volume: 946,701 shs
Average Volume: 1.24 million shs
Market Capitalization: $435.35 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.85

Get Travere Therapeutics alerts:

Travere Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 215.3% Upside
$17.85 Price Target
Short Interest: Bearish
13.93% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.16
Based on 6 Articles This Week
Insider Trading: Selling Shares
$419,773 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.10) to ($1.85) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.08 out of 5 stars

Medical Sector

803rd out of 918 stocks

Pharmaceutical Preparations Industry

363rd out of 419 stocks

3.3

Analyst's Opinion

Consensus Rating
Travere Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 9 buy ratings, 6 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Travere Therapeutics has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
13.93% of the outstanding shares of Travere Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Travere Therapeutics has a short interest ratio ("days to cover") of 8.8.
Change versus previous month
Short interest in Travere Therapeutics has recently increased by 5.26%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Travere Therapeutics does not currently pay a dividend.
Dividend Growth
Travere Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TVTX.

2.3

News and Social Media Coverage

News Sentiment
Travere Therapeutics has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Travere Therapeutics this week, compared to 3 articles on an average week.
Search Interest
5 people have searched for TVTX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Travere Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Travere Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $419,773.00 in company stock.
Percentage Held by Insiders
Only 3.75% of the stock of Travere Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Travere Therapeutics are expected to grow in the coming year, from ($3.10) to ($1.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Travere Therapeutics is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Travere Therapeutics is -3.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Travere Therapeutics has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Travere Therapeutics Stock (NASDAQ:TVTX)

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

TVTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TVTX Stock News Headlines

April 18, 2024 | americanbankingnews.com

Travere Therapeutics' (TVTX) Outperform Rating Reaffirmed at Wedbush

April 14, 2024 | investing.com

Travere Therapeutics CFO sells shares to cover tax obligations

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 4, 2024 | nz.finance.yahoo.com

Stock market today: Stocks slide after Fedspeak as oil surges, March jobs report on deck

April 4, 2024 | globenewswire.com

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

April 3, 2024 | globenewswire.com

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

March 13, 2024 | globenewswire.com

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 13, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Travere Therapeutics on Strong FILSPARI Data and Favorable Regulatory Outlook

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 13, 2024 | markets.businessinsider.com

Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights

March 11, 2024 | markets.businessinsider.com

Travere Therapeutics Submits SNDA Seeking Full Approval Of Filspari In IgA Nephropathy

March 11, 2024 | markets.businessinsider.com

Travere Therapeutics Submits SNDA Seeking Full Approval Of Filspari In IgA Nephropathy

March 11, 2024 | globenewswire.com

Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

February 28, 2024 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (MRNA) and Travere Therapeutics (TVTX)

February 26, 2024 | globenewswire.com

Travere Therapeutics to Present at Upcoming Investor Conferences

February 23, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Expanding Market Potential for Travere Therapeutics’ Sparsentan

February 23, 2024 | msn.com

Travere drug for rare kidney condition recommended for EU approval

February 23, 2024 | globenewswire.com

Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

February 18, 2024 | finance.yahoo.com

TVTX Mar 2024 30.000 call

February 16, 2024 | finance.yahoo.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2023 Earnings Call Transcript

February 16, 2024 | markets.businessinsider.com

Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings)

February 16, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Travere Therapeutics (TVTX) and Grifols SA (GRFS)

February 15, 2024 | msn.com

Travere (TVTX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

February 15, 2024 | finance.yahoo.com

Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

February 15, 2024 | globenewswire.com

Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

February 15, 2024 | msn.com

Travere Therapeutics Q4 2023 Earnings Preview

February 13, 2024 | msn.com

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

See More Headlines

Receive TVTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Travere Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:TVTX
CUSIP: N/A
CIK: 1438533
Web: www.retrophin.com
Phone: (888) 969-7879
Fax: 302-645-1280
Employees: 380
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $17.85
High Stock Price Target: $35.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +212.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.61)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-111,400,000.00
Net Margins: -56.02%
Pretax Margin: -258.96%
Return on Equity: -177.97%
Return on Assets: -44.19%

Debt

Debt-to-Equity Ratio: 1.88
Current Ratio: 3.47
Quick Ratio: 3.41

Sales & Book Value

Annual Sales: $145.24 million
Price / Sales: 3.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.67 per share
Price / Book: 2.14

Miscellaneous

Outstanding Shares: 76,110,000
Free Float: 73,255,000
Market Cap: $435.35 million
Optionable: Optionable
Beta: 0.58

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Eric M. Dube Ph.D. (Age 50)
President, CEO & Director
Comp: $1.4M
Mr. Christopher Cline C.F.A. (Age 39)
Chief Financial Officer
Comp: $709.94k
Ms. Elizabeth E. Reed J.D. (Age 53)
Senior VP, General Counsel & Corporate Secretary
Comp: $713.63k
Dr. William E. Rote Ph.D. (Age 61)
Senior VP and Head of Research & Development
Comp: $748.02k
Mr. Peter Heerma (Age 52)
Chief Commercial Officer
Comp: $742.37k
Ms. Sandra Calvin (Age 58)
SVP, Corporate Controller & Chief Accounting Officer
Ms. Naomi Eichenbaum
Vice President of Investor Relations
Ms. Charlotte Smith
Senior Vice President of Public Affairs
Ms. Angela Giannantonio
Senior Vice President of Human Resources
Mr. Casey Logan
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TVTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Travere Therapeutics stock right now?: 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Travere Therapeutics in the last year. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TVTX shares.
View TVTX analyst ratings or view top-rated stocks.
What is Travere Therapeutics' stock price target for 2024?: 15 equities research analysts have issued twelve-month price targets for Travere Therapeutics' shares. Their TVTX share price targets range from $9.00 to $35.00. On average, they anticipate the company's share price to reach $17.85 in the next year. This suggests a possible upside of 215.3% from the stock's current price.
View analysts price targets for TVTX or view top-rated stocks among Wall Street analysts.
How have TVTX shares performed in 2024?: Travere Therapeutics' stock was trading at $8.99 at the beginning of 2024. Since then, TVTX shares have decreased by 37.0% and is now trading at $5.66.
View the best growth stocks for 2024 here.
When is Travere Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our TVTX earnings forecast.

How were Travere Therapeutics' earnings last quarter?: Travere Therapeutics, Inc. (NASDAQ:TVTX) announced its quarterly earnings data on Thursday, February, 15th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.11. The firm earned $45.06 million during the quarter, compared to analyst estimates of $41.25 million. Travere Therapeutics had a negative trailing twelve-month return on equity of 177.97% and a negative net margin of 56.02%.
What ETF holds Travere Therapeutics' stock?: Virtus LifeSci Biotech Products ETF holds 44,150 shares of TVTX stock, representing 1.52% of its portfolio.
Who are Travere Therapeutics' major shareholders?: Travere Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.12%) and Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include Christopher R Cline, Elizabeth E Reed, Eric M Dube, Jula Inrig, Laura Clague, Noah L Rosenberg, Peter Heerma, Sandra Calvin, Steve Aselage and William E Rote.
View institutional ownership trends.
How do I buy shares of Travere Therapeutics?: Shares of TVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TVTX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial